{"protocolSection": {"identificationModule": {"nctId": "NCT00859898", "orgStudyIdInfo": {"id": "MB102-034"}, "secondaryIdInfos": [{"id": "Eudract #: 2008-007548-33"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes", "officialTitle": "A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2016-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-04"}, "primaryCompletionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-10", "studyFirstSubmitQcDate": "2009-03-10", "studyFirstPostDateStruct": {"date": "2009-03-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-02-04", "resultsFirstSubmitQcDate": "2014-02-04", "resultsFirstPostDateStruct": {"date": "2014-03-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-05-30", "lastUpdatePostDateStruct": {"date": "2016-07-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety of treatment with dapagliflozin will also be assessed in this study"}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Endocrine System Diseases", "Glucose Metabolism Disorders", "Metabolic Diseases", "Metformin", "Dapagliflozin", "Hypoglycemic Agents", "Pharmacologic Actions", "Physiological Effects of Drugs"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1093, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dapagliflozin + Metformin XR", "type": "EXPERIMENTAL", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks", "interventionNames": ["Drug: Dapagliflozin", "Drug: Metformin XR"]}, {"label": "Dapagliflozin + Placebo", "type": "EXPERIMENTAL", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks.", "interventionNames": ["Drug: Dapagliflozin", "Drug: metformin HCl Modified Release matching Placebo"]}, {"label": "Metformin XR + Placebo", "type": "ACTIVE_COMPARATOR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks", "interventionNames": ["Drug: Metformin XR", "Drug: dapagliflozin matching Placebo"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "description": "Tablets, Oral, 10 mg, once daily, 24 weeks", "armGroupLabels": ["Dapagliflozin + Metformin XR", "Dapagliflozin + Placebo"], "otherNames": ["Farxiga\u2122"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Tablets, Oral, up to 2000 mg, once daily, 24 weeks", "armGroupLabels": ["Dapagliflozin + Metformin XR"], "otherNames": ["Glucophage\u00ae"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks", "armGroupLabels": ["Metformin XR + Placebo"], "otherNames": ["Glucophage\u00ae"]}, {"type": "DRUG", "name": "dapagliflozin matching Placebo", "description": "Tablets", "armGroupLabels": ["Metformin XR + Placebo"]}, {"type": "DRUG", "name": "metformin HCl Modified Release matching Placebo", "description": "Tablets", "armGroupLabels": ["Dapagliflozin + Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants", "description": "Adjusted mean change in HbA1c from baseline at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available, ie, last observation carried forward (LOCF) was determined. HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the Double-Blind Period.", "timeFrame": "Week 24"}], "secondaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants", "description": "Data after rescue medication was excluded from this analysis. FPG was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.", "timeFrame": "Week 24"}, {"measure": "Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants", "description": "Therapeutic glycemic response was defined as HbA1c less than 7.0%. n=Number of participants with HBA1c less than (\\<) 7 % at Week 24, last observation carried forward (LOCF) while N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values. Percent=n/N and was adjusted for Baseline HbA1c. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.", "timeFrame": "Week 24"}, {"measure": "Adjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category \u22659.0%", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. The population included those randomized, treated participants whose Baseline HbA1c was greater than, equal to (\\>=) 9.0%. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "Week 24"}, {"measure": "The Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants", "description": "Adjusted mean change from baseline in total body weight at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight was measured in kilograms (kg). Body weight measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.", "timeFrame": "Week 24"}, {"measure": "Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants", "description": "Medical Dictionary for Regulatory Activities (MedDRA), version 12.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Events captured from baseline to last dose plus 4 days for AEs, plus 30 days for SAEs during the Double Blind 12 Week Period. Data after rescue included.", "timeFrame": "Day 1 of Double Blind Period to end of Week 24 Plus 30 days"}, {"measure": "Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants", "description": "Participants with AEs of hypoglycemia, cardiac/vascular disorders, renal impairment or failure, volume depletion (hypotension/dehydration/hypovolemia), fractures, urinary stones, and other reports suggestive of genital infection or urinary tract infection (UTI) were summarized using MedDRA version 13.0. Data after rescue included for all special AEs except hypoglycemia (excluded data after rescue). Major hypoglycemic episode: symptomatic requiring 3rd party assistance due to severe impairment in consciousness or behavior with a glucose value \\< 54 mg/dL and prompt recovery after glucose/glucagon; Minor: either symptomatic with glucose measurement \\< 63 mg/dL, regardless of need for 3rd party assistance, or asymptomatic with glucose \\< 63 mg/dL that does not qualify as major; Other: suggestive but not meeting criteria for major or minor.", "timeFrame": "Baseline to last dose plus 4 days in 12 Week Double Blind Period"}, {"measure": "Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24 - Treated Participants", "description": "Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Blood pressure values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Systolic and Diastolic pressures were measured in millimeters of mercury (mmHg). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "Week 24"}, {"measure": "Mean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants", "description": "Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Heart rate values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently throughout the study. Heart rate was measured in beats per minute (bpm). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "Week 24"}, {"measure": "Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Randomized, Treated Participants", "description": "12-Lead electrocardiograms (ECGs) were performed at entry into Lead-In Period Day -7 visit and Week 24/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator. Baseline (BL) was Day -7 for this parameter. Data after rescue included.", "timeFrame": "Week 24"}, {"measure": "Number of Participants With Marked Laboratory Abnormalities (Not Including Liver Function) in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants", "description": "Laboratory samples: Qualification and Lead-In Periods, Day 1, Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of Double-Blind Period. Baseline (BL)=last assessment prior to start of first dose of double-blind study medication. Data after rescue included. Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); Units per liter (U/L), blood urea nitrogen (BUN). Marked abnormality Low (High) defined: hemoglobin \\<6 (\\>18 females or \\>20 males) g/dL; hematocrit \\<20% ( \\>55% females or \\>60% males); creatinine (\\>=1.5\\*preRX, \\>=2.5 mg/dL); glucose \\<54 (\\>350) mg/dL; creatine kinase (\\>5\\*ULN);calcium \\<7.5 (\\>=1 mg/dL from ULN and \\>= 0.5mg/dL from PreRX); sodium \\<130 or \\< 120 male/female (\\>150 mEq/L; potassium \\<=2.5 (\\>=6.0) mEq/L; bicarbonate \\<= 13 mEq/L; inorganic phosphorus: \\<=1.8 if age 17-65 or \\<=2.1 if age \\>=66, (\\>=5.6 if age 17-65 or \\>=5.1) mg/dL if age \\>=66; albumin \\<=2 (\\>6) g/dL; urine albumin(alb) / creatinine (creat) ratio (\\>1800 mg/g)", "timeFrame": "Baseline to Week 24/end of treatment plus 4 days"}, {"measure": "Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants", "description": "Safety laboratory measurements were obtained during the Qualification and Lead-In Periods and on Day 1 of the Double-Blind Period and at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. BL was defined as the last assessment prior to the start of the first dose of the double-blind study medication. Data included from BL up to and including the last day of treatment plus 30 days. Liver function abnormality criteria: FDA Guidance for Industry: Premarketing Clinical Evaluation (July 2009). Data after rescue was also included. Abbreviations: Pretreatment (PreRX), upper limit of normal (ULN); greater than (\\>) less than (\\<); Units per liter (U/L), alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP). Marked abnormality Low (High) defined: ALP, AST and ALT (\\>3\\*ULN); bilirubin (\\>2\\*ULN if PreRX \\<= ULN; \\>3\\*ULN if PreRX \\> ULN); AST or ALT plus (+) bilirubin elevation: AST or ALT \\>3\\*ULN and bilirubin \\>1.5\\*ULN within 14 days on or after ALT elevation.", "timeFrame": "Baseline to Week 24/end of treatment plus 30 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Treatment naive males and females, \\>= 18 years old and\n\n\\<= 77 years old, with type 2 diabetes mellitus\n\n* Subjects must have central laboratory pre-randomization hemoglobin A1C \\>= 7.5 and \\<= 12.0%\n* C-peptide \\>= 1.0 ng/mL (0.34 nmol/L)\n* Body Mass Index \\<= 45 kg/m2\n* Must be able to perform self monitoring of blood glucose\n\nExclusion Criteria:\n\n* aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \\>3X\\*upper limit of normal (ULN)\n* Serum Total bilirubin \\>2 mg/dL (34.2 \u00b5mol/L)\n* Creatinine kinase \\>3\\*ULN\n* Serum creatinine \\>= 1.50 mg/dL (133 \u00b5mol/L) for male subjects, \\>= 1.40 mg/dL (124 \u00b5mol/L) for female subjects\n* Calcium value outside of the central laboratory normal reference range\n* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases\n* Urine albumin:creatinine ratio (UACR) \\>1800 mg/g (203.4 mg/mmol Cr)\n* Severe uncontrolled hypertension defined as systolic blood pressure (SBP) \\>=180 mmHg and/or diastolic blood pressure (DBP) \\>=110 mmHg\n* Hemoglobin \\>=11.0 g/dL (110 g/L) for men; hemoglobin \\>=10.0 g/dL (100 g/L) for women\n* Positive for hepatitis B surface antigen\n* Positive for anti-hepatitis C virus antibody\n* History of diabetes insipidus\n* History of diabetic ketoacidosis or hyperosmolar nonketotic coma\n* Symptoms of poorly controlled diabetes that would preclude participation in this trial", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "77 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "International Institute Of Clinical Research", "city": "Ozark", "state": "Alabama", "zip": "36360", "country": "United States", "geoPoint": {"lat": 31.45906, "lon": -85.64049}}, {"facility": "Clinical Research Advantage, Inc./Mesa Family Med Ctr, Pc", "city": "Tempe", "state": "Arizona", "zip": "85282", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"facility": "Clinical Research Advantage, Inc.", "city": "Tempe", "state": "Arizona", "zip": "85282", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"facility": "John Muir Physician Network Clinical Research Center", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "Encompass Clinical Research-North Coast", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Southland Clinical Research Center, Inc.", "city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Valley Research", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Del Rosario Medical Clinic, Inc.", "city": "Huntington Park", "state": "California", "zip": "90255", "country": "United States", "geoPoint": {"lat": 33.98168, "lon": -118.22507}}, {"facility": "Irvine Center For Clinical Research, Inc.", "city": "Irvine", "state": "California", "zip": "92618", "country": "United States", "geoPoint": {"lat": 33.66946, "lon": -117.82311}}, {"facility": "Pacific Sleep Medicine Services (Avastra Clinical Trials)", "city": "Redlands", "state": "California", "zip": "92373", "country": "United States", "geoPoint": {"lat": 34.05557, "lon": -117.18254}}, {"facility": "Orange County Research Center", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Lynn Institute Of The Rockies", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Radiant Research, Inc.", "city": "Denver", "state": "Colorado", "zip": "80239", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Clinical Therapeutics Corporation", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Nextphase Clinical Trials, Inc.", "city": "Miami", "state": "Florida", "zip": "33145", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Baptist Diabetes Associates", "city": "Miami", "state": "Florida", "zip": "33156", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Metabolic Research Institute, Inc.", "city": "W Palm Beach", "state": "Florida", "zip": "33401", "country": "United States", "geoPoint": {"lat": 26.71534, "lon": -80.05337}}, {"facility": "Lake Hartwell Family Medicine", "city": "Hartwell", "state": "Georgia", "zip": "30643", "country": "United States", "geoPoint": {"lat": 34.35288, "lon": -82.93209}}, {"facility": "Middle Georgia Drug Study Center, Llc", "city": "Perry", "state": "Georgia", "zip": "31069", "country": "United States", "geoPoint": {"lat": 32.45821, "lon": -83.73157}}, {"facility": "Northwest Clinical Trials", "city": "Boise", "state": "Idaho", "zip": "83704", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Provident Clinical Research", "city": "Addison", "state": "Illinois", "zip": "60101", "country": "United States", "geoPoint": {"lat": 41.9317, "lon": -87.98896}}, {"facility": "Cedar Crosse Research Center", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Deerbrook Medical Associates", "city": "Vernon Hills", "state": "Illinois", "zip": "60061", "country": "United States", "geoPoint": {"lat": 42.21947, "lon": -87.97952}}, {"facility": "Physicians Research Group", "city": "Indianapolis", "state": "Indiana", "zip": "46250", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Borgess Research Institute", "city": "Kalamazoo", "state": "Michigan", "zip": "49048", "country": "United States", "geoPoint": {"lat": 42.29171, "lon": -85.58723}}, {"facility": "Olive Branch Family Medical Center", "city": "Olive Branch", "state": "Mississippi", "zip": "38654", "country": "United States", "geoPoint": {"lat": 34.96176, "lon": -89.82953}}, {"facility": "Clinilabs, Inc.", "city": "New York", "state": "New York", "zip": "10019", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Metrolina Medical Research", "city": "Charlotte", "state": "North Carolina", "zip": "28209", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Pharmquest", "city": "Greensboro", "state": "North Carolina", "zip": "27408", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Crescent Medical Research", "city": "Salisbury", "state": "North Carolina", "zip": "28144", "country": "United States", "geoPoint": {"lat": 35.67097, "lon": -80.47423}}, {"facility": "Community Health Care, Inc.", "city": "Canal Fulton", "state": "Ohio", "zip": "44614", "country": "United States", "geoPoint": {"lat": 40.88978, "lon": -81.59762}}, {"facility": "Holzer Clinic, Inc", "city": "Gallipolis", "state": "Ohio", "zip": "45631", "country": "United States", "geoPoint": {"lat": 38.8098, "lon": -82.20237}}, {"facility": "Wells Institute For Health Awareness", "city": "Kettering", "state": "Ohio", "zip": "45429", "country": "United States", "geoPoint": {"lat": 39.6895, "lon": -84.16883}}, {"facility": "Newark Physician Associates", "city": "Newark", "state": "Ohio", "zip": "43055", "country": "United States", "geoPoint": {"lat": 40.05812, "lon": -82.40126}}, {"facility": "Daniel G. Williams, Md", "city": "Perrysburg", "state": "Ohio", "zip": "43551", "country": "United States", "geoPoint": {"lat": 41.557, "lon": -83.62716}}, {"facility": "Physician Research, Inc.", "city": "Zanesville", "state": "Ohio", "zip": "43701", "country": "United States", "geoPoint": {"lat": 39.94035, "lon": -82.01319}}, {"facility": "Gilbert Medical Research, Llc", "city": "Bethany", "state": "Oklahoma", "zip": "73008", "country": "United States", "geoPoint": {"lat": 35.51867, "lon": -97.63226}}, {"facility": "Tulsa Clinical Research, Llc", "city": "Tulsa", "state": "Oklahoma", "zip": "74104", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Integris Family Care Yukon", "city": "Yukon", "state": "Oklahoma", "zip": "73099", "country": "United States", "geoPoint": {"lat": 35.50672, "lon": -97.76254}}, {"facility": "Williamette Valley Clinical Studies", "city": "Eugene", "state": "Oregon", "zip": "97404", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Dingmans Medical", "city": "Dingmans Ferry", "state": "Pennsylvania", "zip": "18328", "country": "United States", "geoPoint": {"lat": 41.22009, "lon": -74.87128}}, {"facility": "Integrated Medical Group Pc/Fleetwood Clinical Research", "city": "Fleetwood", "state": "Pennsylvania", "zip": "19522", "country": "United States", "geoPoint": {"lat": 40.45398, "lon": -75.81798}}, {"facility": "Wellmon Family Practice", "city": "Shippensburg", "state": "Pennsylvania", "zip": "17257", "country": "United States", "geoPoint": {"lat": 40.05065, "lon": -77.52026}}, {"facility": "Safe Harbor Clinical Research", "city": "E. Providence", "state": "Rhode Island", "zip": "02914", "country": "United States", "geoPoint": {"lat": 41.81371, "lon": -71.37005}}, {"facility": "Southeastern Research Associates, Inc.", "city": "Greenville", "state": "South Carolina", "zip": "29605", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Holston Medical Group", "city": "Bristol", "state": "Tennessee", "zip": "37620", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "Parkway Medical Group", "city": "Fayetteville", "state": "Tennessee", "zip": "37334", "country": "United States", "geoPoint": {"lat": 35.15203, "lon": -86.57055}}, {"facility": "Holston Medical Group", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Southwind Medical Specialists", "city": "Memphis", "state": "Tennessee", "zip": "38125", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Dallas Diabetes & Endocrine Center", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Endocrine Associates", "city": "Houston", "state": "Texas", "zip": "77004", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Village Family Practice", "city": "Houston", "state": "Texas", "zip": "77024", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Juno Research, Llc.", "city": "Houston", "state": "Texas", "zip": "77036", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Non-Invasive Cardiovascular, Pa", "city": "Houston", "state": "Texas", "zip": "77074", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Excel Clinical Research", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Texas Center For Drug Development", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Midland Clinical Research Center", "city": "Midland", "state": "Texas", "zip": "79707", "country": "United States", "geoPoint": {"lat": 31.99735, "lon": -102.07791}}, {"facility": "Hill Country Medical Associates", "city": "New Braunfels", "state": "Texas", "zip": "78130", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"facility": "Covenant Clinical Research, Pa", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "S.A.M. Clinical Research Center", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Avastra Clinical Trials", "city": "Midvale", "state": "Utah", "zip": "84047", "country": "United States", "geoPoint": {"lat": 40.61106, "lon": -111.89994}}, {"facility": "Seven Corners Medical Center", "city": "Falls Church", "state": "Virginia", "zip": "22044", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "Tidewater Integrated Medical Research", "city": "Virginia Beach", "state": "Virginia", "zip": "23454", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"facility": "Northwest Clinical Research Center", "city": "Bellevue", "state": "Washington", "zip": "98007", "country": "United States", "geoPoint": {"lat": 47.61038, "lon": -122.20068}}, {"facility": "Local Institution", "city": "Hyderabad", "state": "Andhra Pradesh", "zip": "500034", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Local Institution", "city": "Aminjikarai", "state": "Chennai", "zip": "600029", "country": "India", "geoPoint": {"lat": 13.07389, "lon": 80.22444}}, {"facility": "Local Institution", "city": "Haryana", "state": "Karnal", "zip": "132001", "country": "India", "geoPoint": {"lat": 29.61611, "lon": 76.98056}}, {"facility": "Local Institution", "city": "Bangalore", "state": "Karnataka", "zip": "560054", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Local Institution", "city": "Indore", "state": "Madhya Pradesh", "zip": "452010", "country": "India", "geoPoint": {"lat": 22.71792, "lon": 75.8333}}, {"facility": "Local Institution", "city": "Nagpur", "state": "Maharashtra", "zip": "440010", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Local Institution", "city": "Nagpur", "state": "Maharashtra", "zip": "440012", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Local Institution", "city": "Chennai", "state": "Tamilnadu", "zip": "600020", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Local Institution", "city": "Ghaziabad", "state": "Uttar Pradesh", "zip": "201002", "country": "India", "geoPoint": {"lat": 28.66535, "lon": 77.43915}}, {"facility": "Local Institution", "city": "Jaipur", "zip": "302001", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "Local Institution", "city": "Bucheon", "state": "Gyeonggi-Do", "zip": "420-717", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Local Institution", "city": "Goyang-Si", "state": "Gyeonggi-Do", "zip": "410773", "country": "Korea, Republic of", "geoPoint": {"lat": 37.65639, "lon": 126.835}}, {"facility": "Local Institution", "city": "Guri-Si", "state": "Gyeonggi-Do", "zip": "471-701", "country": "Korea, Republic of", "geoPoint": {"lat": 37.5986, "lon": 127.1394}}, {"facility": "Local Institution", "city": "Sungnam", "state": "Gyeonggi-Do", "zip": "463-070", "country": "Korea, Republic of"}, {"facility": "Local Institution", "city": "Daegu", "zip": "700-721", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Local Institution", "city": "Incheon", "zip": "405-760", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Local Institution", "city": "Seoul", "zip": "137040", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "CP 44650", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "CP 44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Morelia", "state": "Michioacan", "zip": "58070", "country": "Mexico", "geoPoint": {"lat": 19.70078, "lon": -101.18443}}, {"facility": "Local Institution", "city": "Cuernavaca", "state": "Morelos", "zip": "62448", "country": "Mexico", "geoPoint": {"lat": 18.9261, "lon": -99.23075}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64000", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Merida", "state": "Yucatan", "zip": "97070", "country": "Mexico", "geoPoint": {"lat": 20.97537, "lon": -89.61696}}, {"facility": "Local Institution", "city": "Aguascalientes", "zip": "20230", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "Local Institution", "city": "Durango", "zip": "34000", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Local Institution", "city": "Veracruz", "zip": "CP 91910", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "Local Institution", "city": "Fajardo", "zip": "00738", "country": "Puerto Rico", "geoPoint": {"lat": 18.32579, "lon": -65.65238}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00717", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00909", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00920", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00926", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "Ekaterinaburg", "zip": "620043", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Local Institution", "city": "Kemerovo", "zip": "650029", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Local Institution", "city": "Krasnoyarsk", "zip": "660022", "country": "Russian Federation", "geoPoint": {"lat": 56.01839, "lon": 92.86717}}, {"facility": "Local Institution", "city": "Moscov", "zip": "119048", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "105229", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "125299", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "140091", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Nizhniy Novgorod", "zip": "603018", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Local Institution", "city": "Nizhniy Novgorod", "zip": "603126", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Local Institution", "city": "Novosibirsk", "zip": "630091", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Local Institution", "city": "Novosibirsk", "zip": "630117", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Local Institution", "city": "Saint Petersburg", "zip": "194044", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Saint-Petersburg", "zip": "190068", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Samara", "zip": "443067", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "Local Institution", "city": "Saratov", "zip": "410028", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Local Institution", "city": "Smolensk", "zip": "214018", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Local Institution", "city": "St. Petersburg", "zip": "191015", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St. Petersburg", "zip": "193312", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St.Petersburg", "zip": "191186", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Tyumen", "zip": "625023", "country": "Russian Federation", "geoPoint": {"lat": 57.15222, "lon": 65.52722}}, {"facility": "Local Institution", "city": "Vladimir", "zip": "600023", "country": "Russian Federation", "geoPoint": {"lat": 56.13655, "lon": 40.39658}}, {"facility": "Local Institution", "city": "Volgograd", "zip": "400001", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Local Institution", "city": "Voronezh", "zip": "394018", "country": "Russian Federation", "geoPoint": {"lat": 51.67204, "lon": 39.1843}}, {"facility": "Local Institution", "city": "Yaroslavl", "zip": "150003", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Local Institution", "city": "Yaroslavl", "zip": "150023", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}]}, "referencesModule": {"references": [{"pmid": "26894924", "type": "DERIVED", "citation": "Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Qualification: 660 completed: 28 administrative, 373 no longer met criteria, 1 lack of efficacy, 26 withdrew consent, 1 lost to follow up (LTF), 4 other. Lead-In: 649 entered; 641 completed/ randomized: 1 adverse event, 1 administrative, 4 no longer met criteria, 1 withdrew consent, 1 LTF. Treated 638: 1 LTF, 1 non-compliance, 1 withdrew consent.", "recruitmentDetails": "Participants were recruited from 13-April-2009 to 26-November-2009. Study completed 12-May-2010. Drug naive participants with Type 2 Diabetes Mellitus who had inadequate glycemic control with diet and exercise. Inadequate glycemic control was defined as a hemoglobin A1c (HbA1c) \u2265 7.5% and \u2264 12.0%.", "groups": [{"id": "FG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "FG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.\n\nPlacebo: Metformin hydrochloride (HCl) Modified Release matching placebo tablets, once daily, 24 weeks."}, {"id": "FG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "211"}, {"groupId": "FG001", "numSubjects": "219"}, {"groupId": "FG002", "numSubjects": "208"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "183"}, {"groupId": "FG001", "numSubjects": "188"}, {"groupId": "FG002", "numSubjects": "181"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "31"}, {"groupId": "FG002", "numSubjects": "27"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "11"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "poor/non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "No longer meets criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "non-specified", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants who took at least one dose of double-blind study medication.", "groups": [{"id": "BG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "BG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."}, {"id": "BG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "211"}, {"groupId": "BG001", "value": "219"}, {"groupId": "BG002", "value": "208"}, {"groupId": "BG003", "value": "638"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.0", "spread": "10.13"}, {"groupId": "BG001", "value": "51.1", "spread": "11.53"}, {"groupId": "BG002", "value": "52.7", "spread": "10.38"}, {"groupId": "BG003", "value": "51.6", "spread": "10.72"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Less than (<) 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "190"}, {"groupId": "BG001", "value": "192"}, {"groupId": "BG002", "value": "181"}, {"groupId": "BG003", "value": "563"}]}]}, {"title": "Greater than, equal to (>=) 65 and < 75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "25"}, {"groupId": "BG003", "value": "70"}]}]}, {"title": ">= 75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "5"}]}]}, {"title": "Not Reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Age, Customized", "description": "Female age categorization less than equal to (\\<=) 50 years or greater than (\\>) 50 years.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Female <= 50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "44"}, {"groupId": "BG003", "value": "131"}]}]}, {"title": "Female > 50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "67"}, {"groupId": "BG003", "value": "199"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "105"}, {"groupId": "BG001", "value": "114"}, {"groupId": "BG002", "value": "111"}, {"groupId": "BG003", "value": "330"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "106"}, {"groupId": "BG001", "value": "105"}, {"groupId": "BG002", "value": "97"}, {"groupId": "BG003", "value": "308"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "description": "Ethnicity of participants", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "103"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "63"}, {"groupId": "BG002", "value": "54"}, {"groupId": "BG003", "value": "171"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "123"}, {"groupId": "BG001", "value": "122"}, {"groupId": "BG002", "value": "119"}, {"groupId": "BG003", "value": "364"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "174"}, {"groupId": "BG001", "value": "176"}, {"groupId": "BG002", "value": "166"}, {"groupId": "BG003", "value": "516"}]}]}, {"title": "Black/African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "32"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "82"}]}]}, {"title": "Other Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "8"}]}]}]}, {"title": "Body Mass Index", "description": "Body Mass Index (BMI) was kilograms (kg) body weight divided by height in meters (m) squared (kg/m\\^2). Less than (\\<); Greater than, equal to (\\>=).", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 25 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "66"}]}]}, {"title": ">= 25 kg/m^2 - <27 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "20"}, {"groupId": "BG003", "value": "67"}]}]}, {"title": ">= 27 kg/m^2 - <30 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "49"}, {"groupId": "BG003", "value": "133"}]}]}, {"title": ">= 30 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "123"}, {"groupId": "BG001", "value": "131"}, {"groupId": "BG002", "value": "118"}, {"groupId": "BG003", "value": "372"}]}]}]}, {"title": "Waist Circumference", "description": "The participants waist was measured in centimeters (cm).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "104.33", "spread": "13.678"}, {"groupId": "BG001", "value": "103.86", "spread": "12.805"}, {"groupId": "BG002", "value": "103.03", "spread": "13.224"}, {"groupId": "BG003", "value": "103.75", "spread": "13.225"}]}]}]}, {"title": "Hemoglobin A1c", "description": "Hemoglobin A1c (HbA1c) was reported as percent of hemoglobin.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent of hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.09", "spread": "1.258"}, {"groupId": "BG001", "value": "9.05", "spread": "1.279"}, {"groupId": "BG002", "value": "9.05", "spread": "1.308"}, {"groupId": "BG003", "value": "9.06", "spread": "1.280"}]}]}]}, {"title": "Total Body Weight", "description": "Participants were weighed and weight recorded in kilograms (kg).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "88.43", "spread": "19.668"}, {"groupId": "BG001", "value": "88.53", "spread": "19.334"}, {"groupId": "BG002", "value": "87.24", "spread": "19.423"}, {"groupId": "BG003", "value": "88.08", "spread": "19.452"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants", "description": "Adjusted mean change in HbA1c from baseline at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available, ie, last observation carried forward (LOCF) was determined. HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the Double-Blind Period.", "populationDescription": "N= Number of randomized participants, who took at least 1 dose of double-blind study medication, with non-missing baseline and Week 24 (LOCF) values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent of hemoglobin", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "216"}, {"groupId": "OG002", "value": "203"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.98", "spread": "0.0759"}, {"groupId": "OG001", "value": "-1.45", "spread": "0.0734"}, {"groupId": "OG002", "value": "-1.44", "spread": "0.0757"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant. Two-sided significance level at \u03b1=0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline HbA1c value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.74", "ciUpperLimit": "-0.32", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1056"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant. Two-sided significance level at \u03b1=0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline HbA1c value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.75", "ciUpperLimit": "-0.33", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1072"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The non-inferiority of dapagliflozin 10 mg versus metformin XR was demonstrated when the upper limit of the two-sided 95% confidence interval of the difference in change in HbA1c from baseline to Week 24 (LOCF) between dapagliflozin 10 mg and metformin XR was less than 0.35%.", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.22", "ciUpperLimit": "0.20", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1054"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "When testing for superiority, significance is claimed only if dapagliflozin 10 mg is superior to metformin XR", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9144", "pValueComment": "two-sided significance level at \u03b1=0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline HbA1c value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.22", "ciUpperLimit": "0.20", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1054"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants", "description": "Data after rescue medication was excluded from this analysis. FPG was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.", "populationDescription": "Number analyzed = Number of randomized participants, who took at least 1 dose of double-blind study medication, with non missing baseline and Week 24 (LOCF) values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "216"}, {"groupId": "OG002", "value": "207"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-60.4", "spread": "2.533"}, {"groupId": "OG001", "value": "-46.4", "spread": "2.494"}, {"groupId": "OG002", "value": "-34.8", "spread": "2.545"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A hierarchical closed testing procedure was implemented to control the familywise type I error rate related to this endpoint at the two-sided 0.05 level. Statistical tests were only performed for a given secondary endpoint if all previous sequential tests versus that treatment group were also significant.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "two-sided significance level at \u03b1=0.05. Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-13.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.9", "ciUpperLimit": "-7.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.558"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "A hierarchical closed testing procedure was implemented to control the familywise type I error rate related to this endpoint at the two-sided 0.05 level. Statistical tests were only performed for a given secondary endpoint if all previous sequential tests versus that treatment group were also significant.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "two-sided significance level at \u03b1=0.05. Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-25.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.6", "ciUpperLimit": "-18.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.590"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The non-inferiority of dapagliflozin 10 mg versus metformin XR was demonstrated when the upper limit of the two-sided 95% confidence interval of the difference in change FPG from baseline to Week 24 (LOCF) between dapagliflozin 10 mg and metformin XR was less than 15 mg/dL.", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.6", "ciUpperLimit": "-4.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.566"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "When testing for superiority, significance is claimed only if dapagliflozin 10 mg is superior to metformin XR", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0012", "pValueComment": "two-sided significance level at \u03b1=0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.6", "ciUpperLimit": "-4.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.566"}]}, {"type": "SECONDARY", "title": "Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants", "description": "Therapeutic glycemic response was defined as HbA1c less than 7.0%. n=Number of participants with HBA1c less than (\\<) 7 % at Week 24, last observation carried forward (LOCF) while N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values. Percent=n/N and was adjusted for Baseline HbA1c. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.", "populationDescription": "N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values; N=202, 216, 203, respectively. n=number of responders: 92, 69, 72, respectively. n/N=percent. Percent is then adjusted for baseline HbA1c.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "216"}, {"groupId": "OG002", "value": "203"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "46.6", "lowerLimit": "40.1", "upperLimit": "53.0"}, {"groupId": "OG001", "value": "31.7", "lowerLimit": "25.7", "upperLimit": "37.7"}, {"groupId": "OG002", "value": "35.5", "lowerLimit": "28.8", "upperLimit": "41.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The probability of response was modeled using a logistic regression model with baseline HbA1c as the covariate. Treatment group estimates of response rate were then obtained by integrating each group's modeled probability of response over the observed distribution of baseline covariate (combined across groups).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0012", "pValueComment": "Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Logistic regression based on the methodology of Zhang, Tsiatis and Davidian and Tsiatis, Davidian, Zhang and Lu, with adjustment for baseline HbA1c.", "paramType": "Mean Difference (Final Values)", "paramValue": "14.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.9", "ciUpperLimit": "23.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.598"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The probability of response was modeled using a logistic regression model with baseline HbA1c as the covariate. Treatment group estimates of response rate were then obtained by integrating each group's modeled probability of response over the observed distribution of baseline covariate (combined across groups).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0165", "pValueComment": "Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Logistic regression based on the methodology of Zhang, Tsiatis and Davidian and Tsiatis, Davidian, Zhang and Lu, with adjustment for baseline HbA1c.", "paramType": "Mean Difference (Final Values)", "paramValue": "11.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.1", "ciUpperLimit": "20.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.730"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category \u22659.0%", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. The population included those randomized, treated participants whose Baseline HbA1c was greater than, equal to (\\>=) 9.0%. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "N= Number of randomized participants, who took at least 1 dose of double-blind study medication, with non missing baseline and Week 24 (LOCF) values, whose baseline HbA1c was \\>=9.0%.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent of Hemoglobin", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "97"}, {"groupId": "OG002", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.59", "spread": "0.1249"}, {"groupId": "OG001", "value": "-2.14", "spread": "0.1305"}, {"groupId": "OG002", "value": "-2.05", "spread": "0.1318"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A hierarchical closed testing procedure was implemented to control the familywise type I error rate related to this endpoint at the two-sided 0.05 level. Statistical testing was only performed if the dapagliflozin 10 mg plus metformin XR group was statistically significantly superior to both control groups for the primary efficacy endpoint. Tests were only performed for a given secondary endpoint if all previous sequential tests versus that treatment group were also significant.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0133", "pValueComment": "two-sided significance level at \u03b1=0.05. Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.", "statisticalMethod": "ANCOVA", "statisticalComment": ": treatment group as an effect and the baseline HbA1c value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.81", "ciUpperLimit": "-0.09", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1807"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "A hierarchical closed testing procedure was implemented to control the familywise type I error rate related to this endpoint at the two-sided 0.05 level. Statistical testing was only performed if the dapagliflozin 10 mg plus metformin XR group was statistically significantly superior to both control groups for the primary efficacy endpoint. Tests were only performed for a given secondary endpoint if all previous sequential tests versus that treatment group were also significant.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0036", "pValueComment": "two-sided significance level at \u03b1=0.05. Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant.", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline HbA1c value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.89", "ciUpperLimit": "-0.18", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1817"}]}, {"type": "SECONDARY", "title": "The Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants", "description": "Adjusted mean change from baseline in total body weight at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight was measured in kilograms (kg). Body weight measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.", "populationDescription": "N= Number of randomized participants, who took at least 1 dose of double-blind study medication, with non missing baseline and Week 24 (LOCF) values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "219"}, {"groupId": "OG002", "value": "208"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.33", "spread": "0.2401"}, {"groupId": "OG001", "value": "-2.73", "spread": "0.2346"}, {"groupId": "OG002", "value": "-1.36", "spread": "0.2408"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "A hierarchical closed testing procedure was implemented to control the familywise type I error rate related to this endpoint at the two-sided 0.05 level. Statistical testing was only performed if the dapagliflozin 10 mg plus metformin XR group was statistically significantly superior to both control groups for the primary efficacy endpoint. Tests were only performed for a given secondary endpoint if all previous sequential tests versus that treatment group were also significant.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "two-sided significance level at \u03b1=0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.64", "ciUpperLimit": "-1.30", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3401"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Statistical tests were only performed for a given secondary endpoint if all previous sequential tests versus that treatment group were also significant.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "two-sided significance level at \u03b1=0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "treatment group as an effect and the baseline value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.03", "ciUpperLimit": "-0.71", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3362"}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants", "description": "Medical Dictionary for Regulatory Activities (MedDRA), version 12.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Events captured from baseline to last dose plus 4 days for AEs, plus 30 days for SAEs during the Double Blind 12 Week Period. Data after rescue included.", "populationDescription": "Participants who received at least 1 dose of double-blind study medication during the double-blind treatment period. Data after rescue were also included.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 of Double Blind Period to end of Week 24 Plus 30 days", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "219"}, {"groupId": "OG002", "value": "208"}]}], "classes": [{"title": "Adverse Event (AE)", "categories": [{"measurements": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "132"}, {"groupId": "OG002", "value": "118"}]}]}, {"title": "Related Adverse Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "32"}]}]}, {"title": "Serious Adverse Event (SAE)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Related SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Discontinued due to AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Discontinued due to SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants", "description": "Participants with AEs of hypoglycemia, cardiac/vascular disorders, renal impairment or failure, volume depletion (hypotension/dehydration/hypovolemia), fractures, urinary stones, and other reports suggestive of genital infection or urinary tract infection (UTI) were summarized using MedDRA version 13.0. Data after rescue included for all special AEs except hypoglycemia (excluded data after rescue). Major hypoglycemic episode: symptomatic requiring 3rd party assistance due to severe impairment in consciousness or behavior with a glucose value \\< 54 mg/dL and prompt recovery after glucose/glucagon; Minor: either symptomatic with glucose measurement \\< 63 mg/dL, regardless of need for 3rd party assistance, or asymptomatic with glucose \\< 63 mg/dL that does not qualify as major; Other: suggestive but not meeting criteria for major or minor.", "populationDescription": "Randomized participants who received at least one dose of study medication in the double-blind period. Data after rescue included for all AEs except hypoglycemia, which excluded data after rescue.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to last dose plus 4 days in 12 Week Double Blind Period", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "219"}, {"groupId": "OG002", "value": "208"}]}], "classes": [{"title": "Cardiac Disorder AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Vascular Disorder AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Hypoglycemia AEs (excluding data after rescue)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Hypoglycemia Major Episode", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Hypoglycemia Minor Episode", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Hypoglycemia Other Episode", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "AEs Suggestive of Genital Infection", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "AEs Suggestive of UTI", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": "AEs of Renal Impairment or Failure", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "AEs of Hypotension", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "AEs of Syncope", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "AEs of Fracture", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "AEs of Urinary Stones", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24 - Treated Participants", "description": "Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Blood pressure values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Systolic and Diastolic pressures were measured in millimeters of mercury (mmHg). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "N=number of participants who took at least 1 dose of double-blind study medication, with non missing baseline and Week 24 values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "182"}, {"groupId": "OG001", "value": "185"}, {"groupId": "OG002", "value": "179"}]}], "classes": [{"title": "Systolic (N=182, 185, 179)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.3", "spread": "0.947"}, {"groupId": "OG001", "value": "-4.0", "spread": "0.883"}, {"groupId": "OG002", "value": "-1.2", "spread": "1.010"}]}]}, {"title": "Diastolic (N=182, 185, 179)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "0.579"}, {"groupId": "OG001", "value": "-1.9", "spread": "0.525"}, {"groupId": "OG002", "value": "0.0", "spread": "0.606"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants", "description": "Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Heart rate values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently throughout the study. Heart rate was measured in beats per minute (bpm). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "N=number of participants who took at least 1 dose of double-blind study medication, with non missing baseline and Week 24 values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "bpm", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "182"}, {"groupId": "OG001", "value": "185"}, {"groupId": "OG002", "value": "179"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "0.607"}, {"groupId": "OG001", "value": "-0.1", "spread": "0.593"}, {"groupId": "OG002", "value": "0.5", "spread": "0.594"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Randomized, Treated Participants", "description": "12-Lead electrocardiograms (ECGs) were performed at entry into Lead-In Period Day -7 visit and Week 24/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator. Baseline (BL) was Day -7 for this parameter. Data after rescue included.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "219"}, {"groupId": "OG002", "value": "208"}]}], "classes": [{"title": "Normal at BL, Normal at Week 24 (N=211, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "94"}]}]}, {"title": "Abnormal BL, Normal at Week 24 (N=211, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "22"}]}]}, {"title": "Normal BL, Abnormal at Week 24 (N=211, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": "Abnormal BL, Abnormal at Week 24 (N=211, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "59"}]}]}, {"title": "Normal at BL, Not Reported at Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}]}, {"title": "Abnormal at BL, Not Reported at Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Not Reported at BL, Abnormal at Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Marked Laboratory Abnormalities (Not Including Liver Function) in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants", "description": "Laboratory samples: Qualification and Lead-In Periods, Day 1, Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of Double-Blind Period. Baseline (BL)=last assessment prior to start of first dose of double-blind study medication. Data after rescue included. Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); Units per liter (U/L), blood urea nitrogen (BUN). Marked abnormality Low (High) defined: hemoglobin \\<6 (\\>18 females or \\>20 males) g/dL; hematocrit \\<20% ( \\>55% females or \\>60% males); creatinine (\\>=1.5\\*preRX, \\>=2.5 mg/dL); glucose \\<54 (\\>350) mg/dL; creatine kinase (\\>5\\*ULN);calcium \\<7.5 (\\>=1 mg/dL from ULN and \\>= 0.5mg/dL from PreRX); sodium \\<130 or \\< 120 male/female (\\>150 mEq/L; potassium \\<=2.5 (\\>=6.0) mEq/L; bicarbonate \\<= 13 mEq/L; inorganic phosphorus: \\<=1.8 if age 17-65 or \\<=2.1 if age \\>=66, (\\>=5.6 if age 17-65 or \\>=5.1) mg/dL if age \\>=66; albumin \\<=2 (\\>6) g/dL; urine albumin(alb) / creatinine (creat) ratio (\\>1800 mg/g)", "populationDescription": "N=number of participants who took at least 1 dose of double-blind study medication, with non missing baseline and Week 24 values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to Week 24/end of treatment plus 4 days", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "218"}, {"groupId": "OG002", "value": "207"}]}], "classes": [{"title": "Hematocrit High > 55% (N=209, 218, 206)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Hemoglobin High >18 g/dL(N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Creatinine >1.5*PreRX (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Glucose High > 350 mg/dL (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Albumin low or high (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Calcium Low <7.5mg/dL (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Calcium High >=1mg/dL+ULN (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Bicarbonate Low <=13mEq/L (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Potassium High >=6 mEq/L (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Sodium Low <130 mEq/L (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Sodium High >150 mEq/L (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Sodium Low <120 mEq/L (N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "inorganic phosphorus (high)(N=209, 218, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Urine albumin/creat ratio (high)(N=209, 218, 206)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants", "description": "Safety laboratory measurements were obtained during the Qualification and Lead-In Periods and on Day 1 of the Double-Blind Period and at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. BL was defined as the last assessment prior to the start of the first dose of the double-blind study medication. Data included from BL up to and including the last day of treatment plus 30 days. Liver function abnormality criteria: FDA Guidance for Industry: Premarketing Clinical Evaluation (July 2009). Data after rescue was also included. Abbreviations: Pretreatment (PreRX), upper limit of normal (ULN); greater than (\\>) less than (\\<); Units per liter (U/L), alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP). Marked abnormality Low (High) defined: ALP, AST and ALT (\\>3\\*ULN); bilirubin (\\>2\\*ULN if PreRX \\<= ULN; \\>3\\*ULN if PreRX \\> ULN); AST or ALT plus (+) bilirubin elevation: AST or ALT \\>3\\*ULN and bilirubin \\>1.5\\*ULN within 14 days on or after ALT elevation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to Week 24/end of treatment plus 30 days", "groups": [{"id": "OG000", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "219"}, {"groupId": "OG002", "value": "208"}]}], "classes": [{"title": "AST >3*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "AST >5*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "ALT >3*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "ALT >5*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "ALT >10*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "AST or ALT > 3*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "AST or ALT > 5*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "AST or ALT > 10*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Total bilirubin >1.5*ULN (N=210, 219, 207)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "AST or ALT + Bilirubin (High) (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "ALP >1.5*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "ALP >3*ULN (N=210, 219, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "24 Weeks plus 30 days; Day 1 of double blind treatment to last patient, last visit.", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nPlacebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks.", "seriousNumAffected": 5, "seriousNumAtRisk": 219, "otherNumAffected": 32, "otherNumAtRisk": 219}, {"id": "EG001", "title": "Dapagliflozin + Metformin XR", "description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks\n\nMetformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks", "seriousNumAffected": 3, "seriousNumAtRisk": 211, "otherNumAffected": 26, "otherNumAtRisk": 211}, {"id": "EG002", "title": "Metformin XR", "description": "Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks\n\nPlacebo: Dapagliflozin matching placebo tablets once daily, 24 weeks", "seriousNumAffected": 4, "seriousNumAtRisk": 208, "otherNumAffected": 24, "otherNumAtRisk": 208}], "seriousEvents": [{"term": "Lung abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 208}]}, {"term": "Rectocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Proctalgia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 208}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 208}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 208}]}, {"term": "Vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 219}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 211}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 208}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "AstraZeneca", "organization": "Clinical Trial Transparency", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}